Loading clinical trials...
Loading clinical trials...
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma
Conditions
Interventions
CDK-002
Locations
8
United States
Honor Health
Scottsdale, Arizona, United States
Columbia University/CUMC
New York, New York, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
NEXT Oncology
San Antonio, Texas, United States
The Beatson West of Scotland Cancer Centre/ Gartnavel General Hospital
Glasgow, United Kingdom
Oxford University Hospitals NHS Trust
Headington, United Kingdom
Start Date
September 15, 2020
Primary Completion Date
August 3, 2022
Completion Date
December 23, 2022
Last Updated
February 8, 2023
NCT05720117
NCT06898450
NCT05719558
NCT05098132
NCT07477743
NCT07029399
Lead Sponsor
Codiak BioSciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions